左西孟旦治疗冠心病心功能不全患者的疗效及对生活质量的影响分析

Curative effect and influence of levosimendan on coronary heart disease with cardiac insufficiency and quality of life

目的分析左西孟旦治疗冠状动脉粥样硬化性心脏病(冠心病)心功能不全患者的疗效及对生活质量的影响。方法将2020年8月至2022年8月于亳州市人民医院心血管内科收治的90例冠心病心功能不全患者随机分为对照组和观察组,每组各45例。对照组给予常规治疗,观察组在对照组基础上联合左西孟旦治疗,观察两组患者的心功能指标[左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)左室射血分数(LVEF)]、N末端脑钠肽前体(NT-proBNP)、生活质量(MLHFQ评分)、临床疗效及不良反应(恶心、头晕、头痛、食欲不振)等。结果两组治疗后LVEF均增加,LVEDD、LVESD均减小,且观察组LVEF高于对照组(P<0.05),LVEDD、LVESD低于对照组(P<0.05);两组治疗后的NT-proBNP均降低,且观察组治疗后的NT-proBNP低于对照组(P<0.05);两组治疗后的MLHFQ评分均降低(P<0.05),且观察组治疗后的MLHFQ评分低于对照组(P<0.05);观察组总有效率为95.56%,高于对照组的80.00%(P<0.05);观察组不良反应发生率为17.78%,与对照组的13.33%相近(P>0.05)。结论左西孟旦治疗冠心病心功能不全的疗效较好,可改善患者心功能及心力衰竭标志物,提高生活质量,且不良反应较少,值得临床推广应用。

Objective To analyze the curative effect and influence of levosimendan on coronary heart disease(CHD)with cardiac insufficiency and quality of life(QOL).Methods CHD patients with cardiac insufficiency(n=90)were divided into control group and observation group(each n=45)chosen from Department of Cardiovascular Medicine,People’s Hospital of Bozhou City from Aug.2020 to Aug.2022.The control group was given routine therapy and observation group was additionally given levosimendan treatment.The indexes of heart function[left ventricular end-diastolic inner diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF)],N-terminal pro-brain natriuretic peptide(NT-proBNP),scores of Minnesota Living with Heart Failure Questionnaire(MLHFQ),clinical efficacy and adverse reactions(nausea,dizziness,headache,anorexia)were observed in 2 groups.Results LVEF increased,and LVEDD and LVESD decreased in 2 groups after the treatment,and LVEF was higher(P<0.05)and LVEDD and LVESD were lower(P<0.05)in observation group than those in control group.The level of NT-proBNP decreased in 2 groups after the treatment,and was lower in observation group than that in control group(P<0.05).The scores of MLHFQ decreased in 2 groups after the treatment,and was lower in observation group than that in control group(P<0.05).The total effective rate was 95.56%in observation group and 80.00%in control group(P<0.05).The incidence of adverse reactions was 17.78%in observation group and 13.33%in control group(P>0.05).Conclusion Levosimendan is effective in the treatment of CHD with cardiac insufficiency,and can improve patients’heart function,biomarkers of heart failure and their QOL with less adverse reactions,and is both effective and safe.It is worth to be popularized.